November 19, 2025 - Non-regulatory SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th
November 3, 2025 - Non-regulatory Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion
October 31, 2025 - Non-regulatory SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025
October 28, 2025 - Non-regulatory Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma
September 8, 2025 - Non-regulatory SynAct Pharma AB – Notification of Warrant and Share Transactions by Hunter Capital AB and Heights Capital Management
June 26, 2025 - Non-regulatory A majority of SynAct Pharma’s Board and management have acquired shares with a value of more than SEK 1 million
June 4, 2025 - Non-regulatory SynAct Pharma Refines Development Strategy for Lead Compound Resomelagon (AP1189)
May 12, 2025 - Non-regulatory SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy
April 23, 2025 - Non-regulatory SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy
April 16, 2025 - Non-regulatory SynAct Pharma to participate at BIO International Convention in Boston June 16-19
April 11, 2025 - Non-regulatory SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue
March 17, 2025 - Non-regulatory The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)
March 4, 2025 - Non-regulatory Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
